Individualized Dosing and Therapeutic Drug Monitoring (TDM) of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution
Caroline A. Lindemans(University Medical Center Utrecht), Jaap Jan Boelens(Wilhelmina Children's Hospital), Colin de Haar(Utrecht University), Rick Admiraal(NHS Blood and Transplant), Marc Bierings(University Medical Center Utrecht), Amelia M. Lacna(University Medical Center Utrecht), Stefan Nierkens(Utrecht University), Lysette Ebskamp-van Raaij(University Medical Center Utrecht)
Cited by 1
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
|The Lancet|2012|376
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
|Journal of Clinical Oncology|2020|333